Pretty serious COPD has restricted our evaluation with regard to this
Extremely severe COPD has restricted our analysis with regard to this specific CCR8 drug subgroup. Finally, our outcomes concerning the extent of COPD underdiagnosis and the clinical profile of these sufferers might not be able to become generalised to other overall health care systems; however, the impact of the lack of COPD diagnosis on subsequent hospitalisations and mortality are probably to become typically applicable. The strengths of our study included the large cohort of COPD sufferers, and their homogeneity with respect to incipient COPD hospitalisations, the wide spectrum of disease severity, and length of adhere to up. In addition, the comprehensive multidimensional assessment utilised in our study permitted adjustments for possible confounders.Conclusions This study showed that about one-third of sufferers hospitalised for the first time due to the fact of a COPD exacerbation had not been previously diagnosed (therefore, treated). Also, patients frequently exhibited much less extreme disease, and their danger of re-hospitalisation was decrease when compared with sufferers who had been hospitalised with an established COPD diagnosis. Initial admission as a result of COPD exacerbation gives a window of opportunity for early therapy, in particular for smoking cessation intervention. Additional fileAdditional file 1: Table S1. Characteristics of respiratory diagnoses and pharmacological therapies prior to the first admission for COPD exacerbation in diagnosed COPD patients (n = 225). Table S2. Charlson comorbidities in 342 COPD individuals recruited at their very first hospitalisation for a COPD exacerbation. Comparison amongst undiagnosed and previously diagnosed COPD patients.Balcells et al. BMC Pulmonary Medicine 2015, 15:four biomedcentral.com/1471-2466/15/Page eight ofAbbreviations COPD: Chronic obstructive pulmonary disease; FEV1/FVC: Post-bronchodilator forced expiratory volume in 1 second to forced crucial capacity ratio; FEV1: Post-bronchodilator forced expiratory volume in one second; ERS/ ATS: European Respiratory Society/American Thoracic Society; GOLD: Global initiative for chronic obstructive lung Aurora A Formulation illness; mMRC: Modified health-related research council; DLco: Diffusing capacity for carbon monoxide; 6MWD: Six-minute walking distance; BMI: Body mass index; FFMI: Fat-free mass index; HRQL: Health-related high quality of life; SGRQ: St. George’s respiratory Questionnaire; HADS: Hospital anxiousness and depression scale; CMBD: Minimum Fundamental Dataset; SD: Typical deviation; RV/TLC: Residual volume/total lung capacity; PaO2: Arterial oxygen tension; PaCO2: Arterial carbon dioxide tension. Competing interests Jaume Ferrer has received payments from Novartis, Menarini, Boehringer and Astra-Zeneca for congress help, scientific talks and professional meetings. Authors’ contributions All authors have contributed to (i) the conception and design in the study; (ii) analysis and interpretation of data; and (iii) writing the report or revising it critically for essential intellectual content. EB and JG-A performed the statistical analysis and interpreted the outcomes. EB ready the first draft in the paper. EB and JG-A had complete access to all the information inside the study and take responsibility for the integrity on the information along with the accuracy of your data analysis. All authors study and authorized the final manuscript. Authors’ details The “Phenotype and Course of COPD (PAC-COPD)” Study Group: Centre for Investigation in Environmental Epidemiology (CREAL), Barcelona: Josep M Ant(Principal Investigator), Judith Garcia-Aymerich (project co.
